![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-desktop-headergif-63893.gif)
![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-mobile-headergif-78265.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-302215852.html
https://www.prnewswire.com/news-releases/rigel-provides-update-on-plans-for-snda-for-waiha-program-following-fda-feedback-301645117.html#:~:text=Rigel%20also%20announced%20today%20that,the%20fourth%20quarter%20of%202022.
https://www.prnewswire.com/news-releases/rigel-announces-top-line-results-from-forward-phase-3-clinical-trial-of-fostamatinib-in-patients-with-warm-autoimmune-hemolytic-anemia-301563691.html
https://www.prnewswire.com/news-releases/fostamatinib-meets-primary-endpoint-in-phase-3-trial-in-japan-for-treatment-of-chronic-immune-thrombocytopenia-301448726.html
https://www.prnewswire.com/news-releases/rigel-sharpens-focus-on-its-advanced-portfolio-opportunities-301423729.html
https://www.europeanpharmaceuticalreview.com/news/161903/fostamatinib-reduces-covid-19-risks-by-50-percent-in-phase-ii-study/
https://www.prnewswire.com/news-releases/data-from-nihnhlbi-sponsored-phase-2-trial-of-fostamatinib-in-hospitalized-covid-19-patients-published-in-clinical-infectious-diseases-301366914.html
https://endpts.com/covid-19-roundup-after-a-tiny-sample-size-fda-turns-down-rigels-emergency-use-attempt-for-covid-19-treatment/
https://www.rigel.com/investors/news-events/press-releases/detail/317/fostamatinib-selected-for-nih-activ-4-covid-19-clinical
https://www.prnewswire.com/news-releases/rigel-announces-completion-of-patient-enrollment-for-nihnhlbi-sponsored-phase-2-trial-of-fostamatinib-in-hospitalized-covid-19-patients-301245219.html
https://seekingalpha.com/news/3621051-enrollment-underway-for-rigel-pharmas-fostamatinib-in-mid-stage-covidminus-19-study
https://medicalxpress.com/news/2020-10-fostamatinib-chronic-immune-thrombocytopenia-comparisonadded.html
https://www.biospace.com/article/releases/rigel-announces-nih-nhlbi-sponsored-trial-of-fostamatinib-in-hospitalized-covid-19-patients-in-collaboration-with-inova/
https://www.reuters.com/article/us-health-coronavirus-rigel-fostamatinib/nih-launches-trial-of-rigel-drug-for-severe-covid-19-idUSKBN2681S3
https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-virtual-healthcare-conference-301064907.html
https://www.prnewswire.com/news-releases/rigels-fostamatinib-enters-phase-3-clinical-trial-in-japan-with-kissei-pharmaceuticals-for-the-treatment-of-chronic-immune-thrombocytopenia-300922960.html
https://www.prnewswire.com/news-releases/tavalisse-fostamatinib-disodium-hexahydrate-phase-3-data-published-in-the-american-journal-of-hematology-describes-pivotal-data-and-overall-response-rate-versus-placebo-300638725.html
https://www.fiercepharma.com/pharma/rigel-snags-first-fda-win-approval-for-autoimmune-therapy-tavalisse
https://www.prnewswire.com/news-releases/rigel-announces-fda-approval-of-tavalisse-fostamatinib-disodium-hexahydrate-for-chronic-immune-thrombocytopenia-itp-in-adult-patients-300631702.html
https://endpts.com/rigel-hit-with-another-trial-setback-as-lead-drug-fostamatinib-fails-phii/